Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 42 recruiting now official registry

Anatomic Stage IV Breast Cancer AJCC v8 clinical trials

42 of 60 indexed Anatomic Stage IV Breast Cancer AJCC v8 trials are currently recruiting.

60 US clinical trials · 42 currently recruiting

Anatomic Stage IV Breast Cancer AJCC v8 is the subject of 60 registered US clinical trials on ClinicalTrials.gov, 42 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 47 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 16 of these trials.

The research picture

Anatomic Stage IV Breast Cancer AJCC v8 has 60 registered US clinical trials, 42 of them open to new participants right now, about 70% of the total.

42
recruiting participants now
70%
of trials open to enrollment
4
in Phase 3–4 (later-stage)
16
top sponsor: National Cancer Institute (NCI)
Phase 122Phase 225Phase 33Phase 41

Active & Recent Trials

60 total, page 2 of 2

ACTIVE NOT RECRUITING Phase 2 25 participants

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

Mridula George, MD

NCT04445844

ACTIVE NOT RECRUITING Phase 1 24 participants

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

National Cancer Institute (NCI)

NCT03939897

ACTIVE NOT RECRUITING Phase 1 24 participants

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

National Cancer Institute (NCI)

NCT04345913

ACTIVE NOT RECRUITING Phase 1 23 participants

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT03218826

ACTIVE NOT RECRUITING Phase 1 18 participants

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

University of Washington

NCT04673448

ACTIVE NOT RECRUITING Phase 2 17 participants

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

NCT03179904

ACTIVE NOT RECRUITING Phase 1 14 participants

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

NCT04616248

ACTIVE NOT RECRUITING Phase 1 9 participants

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

City of Hope Medical Center

NCT05081492

ACTIVE NOT RECRUITING Phase 2 8 participants

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Mayo Clinic

NCT03941730

COMPLETED Phase 1 18 participants

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

M.D. Anderson Cancer Center

NCT03207529

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 22
Phase 2 25
Phase 3 3
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Anatomic Stage IV Breast Cancer AJCC v8 Trial Landscape

60 indexed Anatomic Stage IV Breast Cancer AJCC v8 studies · 42 recruiting (70%).

Phase mix: 4 late (III/IV) vs 47 early (I/II).

Top sponsor: National Cancer Institute (NCI) (16 trials), 9 others listed. 10 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Anatomic Stage IV Breast Cancer AJCC v8?

PlainTrial tracks 60 US clinical trials for Anatomic Stage IV Breast Cancer AJCC v8, of which 42 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Anatomic Stage IV Breast Cancer AJCC v8?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.